Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine drug-drug interaction and ECG study with itraconazole in mesothelin-expressing advanced solid cancers
NL-OMON46366Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of anetumab ravtansine in mesothelioma, ovarian cancer, pancreatic cancer (PC) and 6 more (2 arms), sponsored by Bayer. Primary endpoints: ECG parameters, AUC from zero to infinity after first dose and 2 more. Started Dec 2017; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
mesotheliomaovarian cancerpancreatic cancer (PC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46366.